Detalles del proyecto
| Estado | Activo |
|---|---|
| Fecha de inicio/Fecha fin | 4/21/25 → 4/21/27 |
Financiación
- Bicara Therapeutics Incorporated: 21.750,00 US$
24-HN-42-BT(BCA101X301): A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carc
- Arnold, Susanne M (PI)